New hope for breast cancer patients after first treatment fails
NCT ID NCT06263543
Summary
This study is testing whether the drug sacituzumab govitecan can help control metastatic breast cancer in people who have already received another targeted treatment called trastuzumab deruxtecan. The trial will enroll 75 adults with hormone receptor-positive, HER2-low breast cancer that has spread and stopped responding to previous therapies. Researchers want to see if this approved medication remains effective when used as the next treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITINGLos Angeles, California, 90404, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute at Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.